PURPOSE: The purpose of this study was to investigate pigment clumping in idiopathic macular telangiectasia Type 2 for its incidence, development, and progression during the course of the disease. METHODS: Patients with a diagnosis of idiopathic macular telangiectasia Type 2 and >12 months of follow-up were reviewed retrospectively. Measurements of the area of pigment clumping were performed and correlated with visual acuity and findings on spectral domain optical coherence tomography and microperimetry (MP-1). RESULTS: Fifty-three eyes in 27 patients with a mean follow-up of 42.5 ± 14.2 months (range 12-79 months) were included. At study baseline, 16 eyes (30%) had evidence of pigment clumping without associated neovascular changes. During follow-up, 8 of 33 additional study eyes (24%) without previous pigment clumping developed it in Stage 3 (Gass-Blodi classification) disease. Pigment clumping increased in overall area as a function of follow-up time. Pigment clumping was associated with increased intraretinal reflectivity on optical coherence tomography and development of scotomas on microperimetry. CONCLUSION: Pigment clumping commonly develops in Stage 3 idiopathic macular telangiectasia Type 2 disease, enlarges in area continuously over time, and is associated with declining visual function. Longitudinal measurements of the total area of pigment clumping may be helpful in following disease progression and may constitute a useful outcome measure for interventional clinical studies.
PURPOSE: The purpose of this study was to investigate pigment clumping in idiopathic macular telangiectasia Type 2 for its incidence, development, and progression during the course of the disease. METHODS:Patients with a diagnosis of idiopathic macular telangiectasia Type 2 and >12 months of follow-up were reviewed retrospectively. Measurements of the area of pigment clumping were performed and correlated with visual acuity and findings on spectral domain optical coherence tomography and microperimetry (MP-1). RESULTS: Fifty-three eyes in 27 patients with a mean follow-up of 42.5 ± 14.2 months (range 12-79 months) were included. At study baseline, 16 eyes (30%) had evidence of pigment clumping without associated neovascular changes. During follow-up, 8 of 33 additional study eyes (24%) without previous pigment clumping developed it in Stage 3 (Gass-Blodi classification) disease. Pigment clumping increased in overall area as a function of follow-up time. Pigment clumping was associated with increased intraretinal reflectivity on optical coherence tomography and development of scotomas on microperimetry. CONCLUSION: Pigment clumping commonly develops in Stage 3 idiopathic macular telangiectasia Type 2 disease, enlarges in area continuously over time, and is associated with declining visual function. Longitudinal measurements of the total area of pigment clumping may be helpful in following disease progression and may constitute a useful outcome measure for interventional clinical studies.
Authors: Joseph Ho; Andre J Witkin; Jonathan Liu; Yueli Chen; James G Fujimoto; Joel S Schuman; Jay S Duker Journal: Ophthalmology Date: 2010-11-20 Impact factor: 12.079
Authors: Annal D Meleth; Elvira Agrón; Chi-Chao Chan; George F Reed; Kiran Arora; Gordon Byrnes; Karl G Csaky; Frederick L Ferris; Emily Y Chew Journal: Invest Ophthalmol Vis Sci Date: 2005-11 Impact factor: 4.799
Authors: Thomas A Albini; Matthew S Benz; Robert E Coffee; Andrew C Westfall; Rohit R Lakhanpal; Alice R McPherson; Eric R Holz Journal: Ophthalmic Surg Lasers Imaging Date: 2006 Mar-Apr
Authors: Irene Leung; Ferenc B Sallo; Roberto Bonelli; Traci E Clemons; Daniel Pauleikhoff; Emily Y Chew; Alan C Bird; Tunde Peto Journal: Retina Date: 2018-01 Impact factor: 4.256
Authors: Ferenc B Sallo; Irene Leung; Meike Zeimer; Traci E Clemons; Adam M Dubis; Marcus Fruttiger; Daniel Pauleikhoff; Emily Y Chew; Catherine Egan; Tunde Peto; Alan C Bird Journal: Retina Date: 2018-01 Impact factor: 4.256
Authors: Kiran Chandra Kedarisetti; Raja Narayanan; Michael W Stewart; Nikitha Reddy Gurram; Arshad M Khanani Journal: Clin Ophthalmol Date: 2022-10-10